Residual Pituitary Adenomas After Surgical Treatment: Improved Depiction with Gadobenate Dimeglumine Compared to Gadopentetate Dimeglumine

Nicoletta Anzalone¹, Paolo Vezzulli¹, Elisa Scola¹, Piero Picozzi¹, Antonella Iadanza¹, Miles A. Kirchin²

Surgical debulking is often the first approach to management of patients with pituitary adenomas. However, residual adenomatous tissue after surgery is frequent and is associated with a high risk of tumor recurrence. Our intra-individual crossover comparison in 15 patients shows that improved depiction of residual tumor and better differentiation of tumor from adjacent normal structures is achievable on follow-up MRI with gadobenate dimeglumine at 0.1 mmol/kg bodyweight than with gadopentetate dimeglumine at the same dose. Improved tumor depiction allows more accurate definition of the surgical target volume for subsequent gamma knife therapy.